Juan F. Silvestre

Alicante, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Real-world effectiveness and safety of tralokinumab in moderate-to-severe atopic dermatitis with malignancy, chronic infections, and multimorbidity.

Real-world effectiveness and safety of tralokinumab in moderate-to-severe atopic dermatitis with malignancy, chronic infections, and multimorbidity.

Journal: Dermatology and therapy

Published: April 26, 2026

Efficacy of abrocitinib and dupilumab in itch-dominant atopic dermatitis: An analysis of 2 trials.

Efficacy of abrocitinib and dupilumab in itch-dominant atopic dermatitis: An analysis of 2 trials.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 25, 2025

Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis.

Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 24, 2025

Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.

Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.

Journal: American journal of clinical dermatology

Published: February 09, 2025

Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.

Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.

Journal: Lancet (London, England)

Published: September 26, 2024

Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis.

Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis.

Journal: The British journal of dermatology

Published: July 12, 2024

Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study.

Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study.

Journal: International journal of dermatology

Published: May 19, 2024

A re-assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight.

A re-assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight.

Journal: Contact dermatitis

Published: April 23, 2024

Chronic Eczema on Arms due to Aluminum Vaccine Resolved With Dupilumab.

Chronic Eczema on Arms due to Aluminum Vaccine Resolved With Dupilumab.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: March 28, 2024

Successful Treatment of Severe Stasis Dermatitis With Dupilumab: A Case Report.

Successful Treatment of Severe Stasis Dermatitis With Dupilumab: A Case Report.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: January 09, 2024

[Translated article] Recommendations on the Use of Moisturizing Products Prepared by Spanish Dermatologists Using the Delphi Method.

[Translated article] Recommendations on the Use of Moisturizing Products Prepared by Spanish Dermatologists Using the Delphi Method.

Journal: Actas dermo-sifiliograficas

Published: December 28, 2023

2-Hydroxyethyl methacrylate (2-HEMA) sensitization, a global epidemic at its peak in Spain?

2-Hydroxyethyl methacrylate (2-HEMA) sensitization, a global epidemic at its peak in Spain?

Journal: Contact dermatitis

Published: October 22, 2023

Showing 1-12 of 75

Last Updated: 09/26/2026